GEN Exclusives

More »

GEN News Highlights

More »
May 7, 2012

ActiveSite Wins $1.3M to Complete Preclinical Development of Oral Diabetic Macular Edema Drug

  • ActiveSite Pharmaceuticals has been awarded a competitively renewed Phase II SBIR grant of up to $1.3 million by the NIH’s National Eye Institute. It will fund continued preclinical development of its lead orally administered plasma kallikrein (PK) inhibitor for the treatment of diabetic macular edema (DME). ActiveSite says it will use the funds to carry out preclinical safety and toxicology studies required to file an IND application for the start of clinical trials.

    ActiveSitehas previously been awarded funding by the NIH and other sources for its DME program. “The National Eye Institute’s continuing support of ActiveSite’s research efforts to identify and develop a safe, small molecule approach to the treatment of DME has allowed this program to reach this important milestone,” remarks Sukanto Sinha, Ph.D., CEO. “This moves us closer to the goal of bringing this novel, first-in-class, patient-friendly pharmacological approach into the clinic.”

    There are currently no FDA-approved drugs for DME, and, unlike ActiveSite’s PK inhibitor, drug candidates already in late-stage clinical development are delivered intravitreally, the firm notes. Preclinical studies have demonstrated that ActiveSite’s lead PK inhibitor stops diabetes-induced leakage of fluid into the retina in clinically relevant rodent models when delivered systemically.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »